K-numberK242732
Device nameTristel OPH
ApplicantTristel Solutions , Ltd.
Product codeQWS
Device classClass II
Decision dateMay 9, 2025
DecisionSubstantially Equivalent
Regulation880.6886
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Tristel OPH is a high-level disinfectant foam for reprocessing ophthalmic devices that contact mucous membranes, such as diagnostic lenses, tonometer prisms, pachymeters, and retinal imaging probes. It consists of two solutions (Activator and Base) that mix when dispensed to generate chlorine dioxide at ~320 ppm, achieving disinfection in 2 minutes at room temperature when used with single-use Tristel OPH Wipes.

Technological characteristics

Tristel OPH is identical to the predicate Tristel Duo ULT in active chemistry (chlorine dioxide), concentration (~320 ppm), contact time (2 minutes), packaging (dual-compartment dispenser bottle), wipe characteristics (dry, non-woven, low-linting), and shelf life (2 years unopened, 6 months opened). The primary difference is that Tristel OPH requires 2 foam doses per use for smaller ophthalmic devices versus 4 doses for the larger ultrasound probes treated by the predicate.

Test standards cited

AOAC 955.15, 964.02, 955.14, 955.17, 966.04; ASTM E1053; Ascenzi et al., 1987; ISO 10993-5 and ISO 10993-10 for biocompatibility; OSHA and California Division of Occupational Safety and Health standards for inhalation exposure limits.

Substantial equivalence argument

Tristel OPH uses identical chlorine-dioxide chemistry, concentration, contact time, packaging design, and single-use wipe system as the predicate Tristel Duo ULT. Non-clinical testing demonstrates equivalent or superior antimicrobial efficacy (bactericidal, fungicidal, virucidal, mycobactericidal, and sporicidal), biocompatibility, residue safety, and occupational inhalation safety. The only intended-use difference is the category of semi-critical devices (ophthalmic vs. ultrasound), which does not alter the fundamental disinfection mechanism or safety profile, and the smaller foam dose requirement reflects appropriate adaptation to device size rather than a change in performance.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →